NCT00543205View on ClinicalTrials.gov

Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Advanced Melanoma and Normal or ImpairedHepatic Function
Interventions
DRUG

Genasense® (G3139, oblimersen sodium)

Genasense 7 mg/kg/day for 5 days

Sponsors

Lead Sponsor

Genta Incorporated
All Listed Sponsors
lead

Genta Incorporated

INDUSTRY

NCT00543205 - Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment | Biotech Hunter | Biotech Hunter